KR101145181B1 - Black soybean fermentation by monascus sp. for production of body weight reducing material - Google Patents
Black soybean fermentation by monascus sp. for production of body weight reducing material Download PDFInfo
- Publication number
- KR101145181B1 KR101145181B1 KR1020110091137A KR20110091137A KR101145181B1 KR 101145181 B1 KR101145181 B1 KR 101145181B1 KR 1020110091137 A KR1020110091137 A KR 1020110091137A KR 20110091137 A KR20110091137 A KR 20110091137A KR 101145181 B1 KR101145181 B1 KR 101145181B1
- Authority
- KR
- South Korea
- Prior art keywords
- black
- fermentation
- medium
- soybean
- obesity
- Prior art date
Links
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 42
- 244000068988 Glycine max Species 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 238000000855 fermentation Methods 0.000 title claims description 31
- 230000004151 fermentation Effects 0.000 title claims description 31
- 239000000463 material Substances 0.000 title abstract description 7
- 230000037396 body weight Effects 0.000 title description 3
- 241001095209 Monascus sp. (in: Fungi) Species 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 38
- 230000003579 anti-obesity Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 241000030999 Monascus pilosus Species 0.000 claims abstract description 10
- 241001052469 Monascus kaoliang Species 0.000 claims abstract description 6
- 241000031003 Monascus ruber Species 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 244000113306 Monascus purpureus Species 0.000 claims abstract description 5
- 241001107116 Castanospermum australe Species 0.000 claims description 26
- 235000021279 black bean Nutrition 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241000589516 Pseudomonas Species 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 235000009566 rice Nutrition 0.000 claims description 6
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 4
- 238000011218 seed culture Methods 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000010344 sodium nitrate Nutrition 0.000 claims description 3
- 239000004317 sodium nitrate Substances 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 abstract description 9
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 abstract description 9
- 238000010025 steaming Methods 0.000 abstract description 2
- 241001326554 Elaphomycetaceae Species 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 description 14
- 208000008589 Obesity Diseases 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 239000012085 test solution Substances 0.000 description 12
- 229940057059 monascus purpureus Drugs 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 8
- 208000021017 Weight Gain Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000018823 dietary intake Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 241000209094 Oryza Species 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 5
- 239000004410 anthocyanin Substances 0.000 description 5
- 229930002877 anthocyanin Natural products 0.000 description 5
- 150000004636 anthocyanins Chemical class 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000002636 mycotoxin Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229940026314 red yeast rice Drugs 0.000 description 4
- -1 0.2 g Chemical compound 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- QZQXRZXYWVQWAY-UHFFFAOYSA-N 8-(9h-fluoren-9-ylmethoxycarbonylamino)octanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCCCCC(=O)O)C3=CC=CC=C3C2=C1 QZQXRZXYWVQWAY-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000211181 Manta Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000228153 Penicillium citrinum Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- NFGXHKASABOEEW-LDRANXPESA-N methoprene Chemical compound COC(C)(C)CCCC(C)C\C=C\C(\C)=C\C(=O)OC(C)C NFGXHKASABOEEW-LDRANXPESA-N 0.000 description 1
- XXKNHBAFFJINCK-RVEJDSBJSA-N monascin Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCC)C2=C1COC(\C=C\C)=C2 XXKNHBAFFJINCK-RVEJDSBJSA-N 0.000 description 1
- GFSMXLMQRWMHON-UHFFFAOYSA-N monascin Natural products CCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC GFSMXLMQRWMHON-UHFFFAOYSA-N 0.000 description 1
- GIKQHOXMDCDAPT-UHFFFAOYSA-N monascusone B Natural products CC=CC1=CC2=C(CO1)C(=O)C3(C)OC(=O)C(C3C2)C(=O)C GIKQHOXMDCDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000000974 natural food coloring agent Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000009111 xianzhong Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 항비만 활성을 가지는 홍국균을 이용한 검정콩 발효물 및 그 제조방법에 관한 것이다. 더욱 상세하게 본 발명은, 검정콩(흑태)에 홍국균 배양물을 접종하고 발효시켜 얻은, 곰팡이 독소성분인 시트리닌을 생산하지 않으면서 항비만 활성을 갖는 검정콩 발효물에 대한 것이다.
The present invention relates to a black soybean fermented product using the red yeast bacterium having anti-obesity activity and a method for producing the same. More specifically, the present invention relates to a black soybean fermented product having anti-obesity activity without producing citrinin, which is a fungal toxin component obtained by inoculating and fermenting a red yeast cell culture to black soybean (black manta).
홍국(red yeast rice, red koji)은 붉은색의 사상균인 모나스커스(Monascus)속의 균을 곡류에 접종하여 제조한 것이다. 이 균은 중국을 중심으로 동아시아의 여러 지역에서 천연의 식품 착색제나 가공품 및 소화 촉진과 혈류 개선의 소재로서 오랫동안 사용되어 왔다.Red yeast rice (red koji) is prepared by inoculating grains of the genus Monascus, a red filamentous fungus. The bacterium has long been used as a natural food colorant and processed product in various parts of East Asia, mainly in China, as a material for promoting digestion and improving blood flow.
근래에는 홍국균이 생성하는 2차 대사산물인 메비놀린(혹은 로바스타틴(lovastatin), 모나콜린(monacolin) K, 및 메바코르(mevacor),C24H36O5)가 콜레스테롤 생합성효소인 HMG-CoA(3-hydroxy-methyl-3-glutaryl-coenzyme) 환원효소를 강력하게 저해하여 혈중지질 농도와 콜레스테롤 합성 저하에 따른 각종 기능성이 보고되어(Wang IK et al., J. Agri. Food Chem. 48: 3183-3189 2000; Endo A. et al., J. Antibiotechnol. 38: 420-422 1985; Manzoni M & Rollini M. App. Microbiol. Biotechnol. 58: 555-564 2002; Wei W. et al., J. Nutri. Biochem. 14: 314-318 2003) 주목을 받고 있다.Recently, the second metabolite produced by Rhesus bacteria, mebinolin (or lovastatin, monacolin K, and mebacor, C 24 H 36 O 5 ), is a cholesterol biosynthesis HMG-CoA ( 3-hydroxy-methyl-3-glutaryl-coenzyme) strongly inhibited reductase and reported various functionalities due to lowered lipid concentration and cholesterol synthesis (Wang IK et al., J. Agri. Food Chem. 48: 3183 -3189 2000; Endo A. et al., J. Antibiotechnol. 38: 420-422 1985; Manzoni M & Rollini M. App.Microbiol.Biotechnol. 58: 555-564 2002; Wei W. et al., J. Nutri. Biochem. 14: 314-318 2003).
그러나 모나스커속 균주는 대사 산물로서 메비놀린 이외에도 모나스코루브라민(monascorubramin)이나 모나신(monascin) 등의 색소성분과 함께, 신장과 간장의 독 성분으로 알려진 시트리닌 등의 마이코톡신(mycotoxin)을 생산한다(Blanc PJ, Loret MO, Goma G.Biotechnol. Lett. 17: 291-294 1995; Wang YZ, Ju XL, Zhou YG. Food Microbiol. 22: 145-148 2005). 이는 모나스커스속 균주의 광범위한 활용에 장애가 될 수 있다. However, the genus Monasker is a mycotoxin such as citrinin, which is known as a poison component of kidney and liver, along with pigment components such as monascorubramin and monascin, in addition to mevinolin as a metabolite. (Blanc PJ, Loret MO, Goma G. Biotechnol. Lett. 17: 291-294 1995; Wang YZ, Ju XL, Zhou YG. Food Microbiol. 22: 145-148 2005). This can impede the widespread use of the Monascus strain.
즉, 이들 2차 대사산물의 생산은, 균체 내에서 아세틸-코에이(acetyl-coA)와 말로닐-코에이(malonyl-coA)로 개시되는 폴리케타이드 경로(polyketide pathway)를 동일하게 경유하여 생합성(Hendrickson L. et al., Chem. Biol. 6: 429-439 1999; Shinizu T. et al., Appl. Environ. Microbiol. 71:3453-3457 2005) 되기 때문이다. That is, the production of these secondary metabolites is via the same polyketide pathway initiated by acetyl-coA and malonyl-coA in cells. Biosynthesis (Hendrickson L. et al., Chem. Biol. 6: 429-439 1999; Shinizu T. et al., Appl. Environ. Microbiol. 71: 3453-3457 2005).
최근 Wang 등은 여러 종의 모나스커스의 배양물에 함유된 시트리닌의 양을 측정한 결과, 조사된 모든 시료에서 최고 480 ㎎/L에서 최저 65 ㎎/L의 시트리닌이 검출되어, 모나스커스 균주를 이용한 모든 제품에 대한 안전성 평가의 필요성을 제기 하였다(Wang YZ, Ju XL, Zhou YG. Food Microbiol. 22: 145-148 2005).Recently, Wang et al. Measured the amount of citrinin in cultures of several species of Monascus. As a result, Monascus strains were detected in all samples examined at a maximum of 480 mg / L and at least 65 mg / L. The necessity of safety evaluation of all products using WP (Wang YZ, Ju XL, Zhou YG. Food Microbiol. 22: 145-148 2005) was raised.
시트리닌은 1931년에 밝혀진 곰팡이의 대사 산물로서, 신장과 간장의 기능에 영향을 주는 곰팡이 독소성분으로 알려져 왔다. 특히 페니실리움 시트리눔(Penicillium citrinum)에서 분리하여 시트리닌(citrinin)으로 명명되었으나, 이후에 아스퍼질러스(Aspergillus)나 모나스커스(Monascus)속 곰팡이의 대사산물에서도 그 존재량이 0.065-0.48 ㎎/㎖로 알려졌다.Citrinin is a fungal metabolite that was discovered in 1931 and has been known as a fungal toxin that affects the function of the kidneys and liver. In particular, it was separated from penicillium citrinum and named as citrinin, but its presence was also present in the metabolite of Aspergillus or Monascus fungus 0.065-0.48 mg / Known as ml.
지금까지 홍국 배양물의 제조는 대부분 액상배양의 심부발효법(submerged fermentation)을 이용한 것으로, 주로 색소 성분을 얻기 위한 최적의 발효조건 및 균주탐색, 홍국을 첨가한 기능성 제품의 제조 등이 연구되어 왔다. 고체발효법(solid state fermentation) 역시, 색소를 비롯한 일부 기능성 성분을 얻기 위한 수단으로 시도되었지만, 사용된 배지의 주요 곡물은 쌀이 대부분이고 그 밖에 보리와 밀이 사용되었으며, 콩은 홍국균에 의한 성공적인 발효의 전례가 없어 홍국발효에 적합하지 않은 곡물로 알려져 왔다.
Until now, most of the culture of red yeast rice was made by submerged fermentation of liquid culture, and mainly, optimum fermentation conditions, strain detection, and production of functional products containing red yeast rice have been studied. Solid state fermentation has also been attempted as a means of obtaining some functional ingredients, including pigments, but the main grains used in the medium were mostly rice, barley and wheat were used, and soybeans were successfully fermented by S. aureus. It is known that grains that are not suitable for fermented red yeast rice are unprecedented.
본 발명은 상기한 바와 같은 종래의 문제점을 해결하기 위해 제안된 것으로, 본 발명 목적은 항산화 활성이 뛰어난 검정콩에 홍국균을 접종하여 고체 발효방법을 통하여 발효시킴으로써, 곰팡이 독소성분인 시트리닌 생산을 하지 않는 안전한 항비만 효능이 있는 물질을 대량 생산하는 방법을 제공하기 위한 것이다.
The present invention has been proposed to solve the conventional problems as described above, the object of the present invention is to inoculate hongguk bacteria to black beans having excellent antioxidant activity by fermentation through a solid fermentation method, does not produce the toxin component citrinin It is to provide a method for mass production of a substance having a safe anti-obesity effect.
본 발명은 검정콩에 모나스커스 퍼푸레우스(M. purpureus), 모나스커스 필로수스(M. pilosus), 모나스커스 루버(M. ruber) 및 모나스커스 카올리앙(M. kaoliang) 중에서 선택된 하나 이상의 홍국균 종배양액을 접종하고 발효시켜 얻은, 항비만 활성을 갖는 검정콩 발효물을 제공한다. The present invention Pseudomonas coarse fur pure mouse (M. purpureus), Pseudomonas coarse Philo Versus (M. pilosus), Pseudomonas coarse louver (M. ruber) and Pseudomonas coarse car up hem (M. kaoliang) one or more selected from the soybean honggukgyun It provides a black bean fermented product having anti-obesity activity obtained by inoculating and fermenting the seed culture solution.
상기 홍국균은 모나스커스 필로수스(M. pilosus) KCCM 60084, 모나스커스 필로수스(M. pilosus) IFO4480, 모나스커스 루버(M. ruber) ATCC22080 또는 모나스커스 카올리앙(M. kaoliang) KCCM 60154일 수 있다.The red yeast bacillus may be M. pilosus KCCM 60084, M. pilosus IFO4480, M. ruber ATCC22080 or M. kaoliang KCCM 60154 have.
상기 검정콩은 증자한 검정콩, 분쇄된 검정콩, 발아된 검정콩, 볶은 검정콩, 통밀과 혼합한 검정콩 및 이들의 가공품으로 이루어진 군으로부터 선택될 수 있다.The black beans may be selected from the group consisting of black beans, crushed black beans, germinated black beans, roasted black beans, black beans mixed with whole wheat and processed products thereof.
다른 측면에서 본 발명은, In another aspect, the present invention,
검정콩을 증자하고; 그리고 Add black beans; And
상기 증자된 검정콩에 모나스커스 앵카(M. anka), 모나스커스 퍼푸레우스(M. purpureus), 모나스커스 필로수스(M. pilosus), 모나스커스 루버(M. ruber) 및 모나스커스 카올리앙(M. kaoliang) 중에서 선택된 하나 이상의 홍국균 종배양액을 접종하고 발효시키는 단계를 포함하는 항비만 활성을 갖는 검정콩 발효물의 제조방법을 제공한다. Monascus Anka, M. purpureus , M. purlos , M. pilosus , M. ruber and Monascus kaolin M. kaoliang ) provides a method for producing a black soybean fermented product having anti-obesity activity comprising the step of inoculating and fermenting one or more hongguk species culture medium selected from.
상기 발효 단계는 상기 홍국균 종배양액을 중량비 1-10 중량% 되게 상기 검정콩에 첨가하여 20~30℃에서 10~40일간 발효시키는 단계일 수 있다.The fermentation step may be a step of fermenting 10 to 40 days at 20 ~ 30 ℃ by adding to the black soybean seed culture medium to 1-10% by weight.
상기 홍국균 종배양액은 감자한천배지(PDA배지)에서 배양한 홍국균을 액체 영양배지에 접종하여 배양할 수 있다.The hongguk species culture medium can be cultured by inoculating the honggukyun cultured in potato agar medium (PDA medium) in a liquid nutrient medium.
상기 액체 영양배지의 조성은 쌀가루 2.0g, 글루코오스 3.0 g, 펩톤 2.0 g, KH2PO4 0.8 g, MgSO4?7H2O 0.05 g, 소듐니트레이트 0.2 g, NaCl 0.1 g, d-워터 100 mL의 조제비율과 초기 pH 6.0의 배지일 수 있다.
The composition of the liquid nutrient medium is a rice flour 2.0g, glucose 3.0 g, peptone 2.0 g, KH 2 PO 4 0.8 g, MgSO 4? 7H 2 O 0.05 g, sodium nitrate, 0.2 g, NaCl 0.1 g, d-
검정콩(흑태)은 옛날부터 한방에서 오두(烏頭)라 불리는 약 콩으로 허약체질, 무기력증, 불안감의 해소와 각기병 예방, 약물중독, 식중독 등에도 효과가 있는 것으로 알려져 있다. 동의보감에 의하면 검정콩의 종피가 혈액을 자양하고, 풍을 소통시키며, 시력증진 및 뇌를 맑게 하고 두통치료에도 효과가 있다고 하였다. Black bean (black tae) is a traditional soybean called Odu (한) in oriental medicine. It is known to be effective in weakening constitution, lethargy, relieving anxiety, preventing each disease, drug addiction and food poisoning. According to the agreement, black soybean seed nourish blood, communicate wind, improve vision, clear the brain and treat headache.
또한, 검정콩의 경우, 안토시아닌이라는 항산화 물질을 많이 포함하고 있어 영양기능 이외의 질병예방 및 치료기능의 생체활성 성분을 많이 포함하고 있는 효용가치가 매우 높은 식품소재 중 하나이다. In addition, black soybean is one of the food materials with high utility value, which contains a lot of antioxidant substance called anthocyanin, which contains a lot of bioactive ingredients for disease prevention and treatment functions other than nutritional function.
본 발명에서는 지금까지 시도되지 않았던 검정콩을 대상으로, 곰팡이 독소성분인 시트리닌을 생산하지 않으면서 항비만 효과가 있는 홍국균 발효를 시도하였다. 먼저, 모나스커스속 균주를 이용하여 우량 균주를 선발하였고, 액체영양배지에서의 시트리닌이 검출되지 않음을 확인하고, 천연 배지로는 기존에 홍국발효의 기질로 가장 많이 사용해 오던 쌀 대신 안토시아닌 함량이 높은 검정콩을 이용한 고체 발효를 실시하였다. 그러나, 검정콩의 경우 쌀과 같은 곡류에 비하여 단백질 함량이 매우 높은 반면 전분당 함량이 매우 낮은 단점을 극복하기 위하여 액체 종배양액의 사용과 더불어 통밀을 이용할 수도 있다.In the present invention, the black soybean, which has not been attempted until now, attempted the fermentation of red yeast bacteria having an anti-obesity effect without producing the fungal toxin component citrinin. First, a superior strain was selected using the strain of Monascus, and it was confirmed that citrine was not detected in the liquid nutrient medium, and the anthocyanin content instead of the rice which was previously used most as a substrate of red yeast fermentation as a natural medium. Solid fermentation was performed using high black beans. However, black soybeans may use whole wheat in addition to the use of liquid culture medium to overcome the disadvantage of very high protein content but very low starch sugar content compared to grains such as rice.
비만은 체내에 지방조직이 과도하게 축적되어 있는 상태를 말한다. 비만은 당뇨병, 동맥경화, 심혈관질환, 고혈압, 고지혈증 등 심각한 성인병을 유발하는 가장 큰 원인이다. 비만의 발생 원인이나 비만의 치료 및 예방법에 대한 연구는 전 세계적으로 활발히 진행되고 있으며, 특히 항비만 기능성 식품에 대한 연구가 활발히 진행되고 있다. Obesity is a condition in which fat tissue is excessively accumulated in the body. Obesity is the leading cause of serious adult illness, including diabetes, arteriosclerosis, cardiovascular disease, hypertension, and hyperlipidemia. Research into the causes of obesity, treatment and prevention of obesity is being actively conducted around the world, especially research on anti-obesity functional foods.
기능성 식품 중에 검정콩은 안토시아닌이라는 항산화 활성 물질을 많이 함유하고 있다. 안토시아닌은 검정콩에 많이 함유되어 있는 유색소로서 항균성, 항산화 효과, 항암, 항비만에 효과가 있다고 알려져 있다. Black beans contain many antioxidants called anthocyanins. Anthocyanin is a pigment that is contained in black soybeans and is known to have antimicrobial, antioxidant, anticancer and anti-obesity effects.
또한 검정콩 펩타이드가 비만에 효과가 있다는 결과 발표(국내 특허출원10-2007-0133156)도 있다.
There is also a report stating that black soybean peptides are effective in obesity (domestic patent application 10-2007-0133156).
본 발명에 따른 홍국균을 이용한 검정콩 발효물은 독소 성분인 시트리닌을 생산하지 않으면서 항비만 활성을 가지는 발효물을 제공하는 효과가 있다.
Black soybean fermentation product using red yeast bacteria according to the present invention has the effect of providing a fermentation product having anti-obesity activity without producing the toxin component citrinin.
도 1은 발효 방법과 조건을 서로 달리한 검정콩 발효물의 총 폴리페놀 함량을 나타낸 것으로, 데이타는 3회 측정 평균값과 표준편차이다.
도 2는 발효 방법과 조건을 서로 달리한 검정콩 발효물의 전자공여 활성능(DPPH소거능)을 나타낸 것으로, 데이타는 3회 측정 평균값과 표준편차이다.
도 3은 발효 방법과 조건을 서로 달리한 검정콩 발효물의 SOD 유사활성을 나타낸 것으로, 데이타는 3회 측정 평균값과 표준편차이다.
도 4는 발효 방법과 조건을 서로 달리한 검정콩 발효물의 모나콜린 함량의 차이를 나타낸 것으로, 데이터는 3회 반복실험의 측정결과 평균값과 표준편차이다.
도 5는 고지방식이 동물모델 식이에서의 비만 효과를 나타낸 것으로 데이타는 3회 반복실험의 측정결과 평균값과 표준편차이다.Figure 1 shows the total polyphenol content of black soybean fermentation with different fermentation methods and conditions, the data is the average value and standard deviation of three measurements.
Figure 2 shows the electron donating activity (DPPH scavenging ability) of the black soybean fermentation with different fermentation methods and conditions, the data is the average value and the standard deviation of three measurements.
Figure 3 shows the SOD-like activity of the black soybean fermentation with different fermentation methods and conditions, the data are three times the average value and the standard deviation.
Figure 4 shows the difference in the monacholine content of black soybean fermentation with different fermentation methods and conditions, the data is the average value and standard deviation of the measurement results of three replicates.
Figure 5 shows the effect of obesity in the diet of the high-fat diet animal model, the data is the mean value and standard deviation of the measurement results of three replicates.
이하 본 발명의 이해를 돕기 위해 바람직한 실시예를 통하여 좀 더 구체적으로 제시한다. 그러나 하기의 실시예는 본 발명을 예시하는 것일 뿐 본 발명이 하기의 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. However, the following examples are merely to illustrate the present invention is not limited to the following examples.
[실시예 1] 재료 및 방법Example 1 Materials and Methods
한국종균협회에서 분양받은 Monascus pilosus KCCM 60084, Monascus pilosus IFO4480, Monascus ruber ATCC22080, Monascus kaoliang KCCM 60154를 사용하였다. 검정콩과 통밀은 은 2010년에 수확한 것을 구입해서 사용하였다.
Monascus pilosus KCCM 60084, Monascus pilosus IFO4480, Monascus ruber ATCC22080, and Monascus kaoliang KCCM 60154 were used. Black beans and whole wheat were harvested and used in the silver harvest in 2010.
[실시예 2] 종균 배양Example 2 Spawn Culture
먼저 모든 균주들을 PDA배지(potato dextrose agar, Difco, MI, USA)를 이용하여 28℃에서 4일 배양한 다음, S-INAE 배지(쌀가루 2.0g, 글루코오스 3.0 g, 펩톤 2.0 g, KH2PO4 0.8 g, MgSO4?7H2O 0.05 g, 소듐니트레이트 0.2 g, NaCl 0.1 g, d-워터 100 mL, pH 6.0)를 넣은 캡시험관에, 앞서 언급한 균주들을 이식하여 30℃의 쉐이킹 인큐베이터(150 rpm)에서 10일간 배양한 후, 동일 배지 1 L에 접종하여 Jar Fermenter(Value kio-Reactor, kiotron, Korea)에서 30℃를 유지하면서 10일간 통기 배양하여 스타터로 사용하였다.
First, all the strains were incubated at 28 ° C. for 4 days using PDA medium (potato dextrose agar, Difco, MI, USA), and then S-INAE medium (rice flour 2.0 g, glucose 3.0 g, peptone 2.0 g, KH 2 PO 4). In a cap test tube containing 0.8 g, MgSO 4 ˜7H 2 O 0.05 g, sodium nitrate 0.2 g, NaCl 0.1 g, d-
[실시예 3] 홍국검정콩 발효물의 제조Example 3 Preparation of Hongguk Black Soybean Fermented Product
검정콩을 세척한 후 1 내지 3배수의 물에 10~16 시간 동안 침지시킨 다음 여분의 물기를 제거한 후 그대로 증자하거나 침지시킨 콩을 분쇄하여 증자하거나, 콩을 분쇄하여 가루로 만든 다음 수분을 30~60% 첨가하여 증자하는 방거나 또는 콩을 침지한 후 싹을 낸 후 분쇄하여 증자하는 방법을 이용하여 검정콩을 준비하였다. After washing black beans, immerse them in 1 ~ 3 times of water for 10 ~ 16 hours, then remove excess water and then increase or increase the soaked beans by crushing them. Black beans were prepared using a method of increasing the amount of 60% of steaming or bean soaking, sprouting, pulverizing, and cooking.
상기와 같이 제조된 시료에 S-INAE 배지에 배양한 홍국 종균을 5~10% 첨가하여 24~30℃에서 10~50일 발효시킨 다음 40~60℃로 열풍건조한 후 분쇄하여 홍국검정콩 발효물을 얻었다.5 to 10% of red yeast seed cultured in S-INAE medium was added to the sample prepared as described above, fermented at 24 to 30 ° C. for 10 to 50 days, and then hot-air dried at 40 to 60 ° C. to grind red fermented soybean black fermented product. Got it.
대조군으로는, 검정콩을 100 메쉬 크기로 분쇄한 콩가루에 수분을 첨가하지 않고 90분간 증자한 것을 사용하였다. As a control, the black bean was cooked for 90 minutes without adding water to the soy flour pulverized into a 100 mesh size.
다양한 발효 방법과 조건에 따라 얻어진 발효물은 다음 표 1과 같다.Fermented products obtained according to various fermentation methods and conditions are shown in Table 1 below.
[표 1][Table 1]
[실시예 4] 열수추출Example 4 Hot Water Extraction
상기 표 1에서 얻은 검정콩 발효물을 가지고 열수추출액을 조제하였으며, 총 폴리페놀 및 총 플라보노이드 함량과 항산화능 분석용 시액으로 이용하였다. 열수추출은 이 기술분야에 공지된 방법을 사용하였다.
The hot water extract was prepared with the black soybean fermented product obtained in Table 1, and was used as a total polyphenol and flavonoid content and an assay for antioxidant activity. Hot water extraction used a method known in the art.
[실시예 5] 총폴리페놀 함량Example 5 Total Polyphenol Content
폴리페놀은 강력한 항산화력을 가지고 있어 인체조직에 함유된 지질성분들이 산화됨으로서 나타나는 각종 질환을 예방하거나 치유하는 효과를 나타낸다. 따라서 본 발명은 강력한 항산화효과, 항암, 항비만 효과가 있다고 알려진 안토시아닌을 많이 함유하고 있는 검정콩을 이용하여 홍국균을 발효하여 제조하고 총 폴리페놀함량을 조사하였다. Polyphenols have a strong antioxidant power, which prevents or cures various diseases caused by oxidation of lipid components in human tissues. Therefore, the present invention was prepared by fermenting erythrocytes using black soybeans containing a lot of anthocyanins known to have strong antioxidant effects, anti-cancer and anti-obesity effects, and investigated the total polyphenol content.
Dewanto 등(Dewanto V, Xianzhong W, Liu RH. 2002. Processed sweet corn has higher antioxidant activity. J Agric Food Chem 50: 4959-4964.)의 방법에 따라 시액 100 μL에 2%, 소듐 카보네이트 2 mL과 50% Folin-Ciacalteu reagent 100 μL을 가한 후 720 nm에서 흡광도를 측정하였으며 갈릭산(Sigma-Aldrich, St. Louis, MO, USA)의 검량선에 의하여 함량을 산출하였다. According to the method of Dewanto et al. (Dewanto V, Xianzhong W, Liu RH. 2002. Processed sweet corn has higher antioxidant activity.J Agric Food Chem 50: 4959-4964.) 2% in 100 μL of the solution, 2 mL of sodium carbonate and 50 After adding 100 μL of% Folin-Ciacalteu reagent, the absorbance was measured at 720 nm, and the content was calculated by the calibration curve of gallic acid (Sigma-Aldrich, St. Louis, MO, USA).
그 결과 도 1에 나타내는 바와 같이, 대조군인 B3보다 본 발명에 따른 검정콩 발효물의 총폴리페놀 함량이 높게 나타났다. 구체적으로, 총폴리페놀 함량은 B2M3, B2M4, B3ME, B3MG에서는 발효물 g당 각각 30 mg 이상이었고, B1M2, B1M3, B1M4, B2M1,B3MH에서는 각각 20 mg 이상으로 B1M1, B3, B3MD, B3MF, MPM의 경우는 10 mg 이상으로 나타났다.
As a result, as shown in Figure 1, the total polyphenol content of the black bean fermentation according to the present invention was higher than the control group B3. Specifically, the total polyphenol content was 30 mg or more per g of fermentation in B2M3, B2M4, B3ME, and B3MG, respectively, and 20 mg or more in B1M2, B1M3, B1M4, B2M1, and B3MH, respectively, and B1M1, B3, B3MD, B3MF, and MPM. In case of more than 10 mg appeared.
[실시예 6] 전자공여능(electron donating ability)Example 6 electron donating ability
전자공여능은 생체내 활성산소라디칼에 수소이온(H+)이 결합함으로써 산화를 방어하는 하나의 지표로 이용되며, 수치가 높을수록 높은 항산화활성을 나타낸다. Electron donating ability is used as an indicator to prevent oxidation by the binding of hydrogen ions (H +) to active oxygen radicals in vivo, the higher the value shows higher antioxidant activity.
Blois(Blois MS. 1958. Antioxidant determination by the use of a stable free radical. Nature 181: 1198-1200.)의 방법에 따라 시료 추출액 0.2 mL에 0.4 mM DPPH (1,1diphenyl-2- picryl-hydrazyl)용액 0.8 mL를 가하여 보텍스로 혼합하고 10분간 방치 한 다음 520 nm에서 흡광도를 측정하였으며 계산식, 전자공여능(%) = 100 - [(OD of sample/OD of control) x 100]에 의하여 활성도를 산출하였다. 0.4 mM DPPH (1,1diphenyl-2-picryl-hydrazyl) solution in 0.2 mL of the sample extract according to Blois (Blois MS. 1958. Antioxidant determination by the use of a stable free radical.Nature 181: 1198-1200.) 0.8 mL was added, mixed with vortex, left for 10 minutes, and the absorbance was measured at 520 nm. The activity was calculated by the formula, electron donating ability (%) = 100-[(OD of sample / OD of control) x 100].
도 2는 본 발명에 따른 검정콩 발효물의 전자공여능의 변동을 조사한 결과로, mL당 검정콩 발효물의 열수추출액의 전자공여능은 대조구로 사용한 B3에서 가장 낮은 경향을 나타내었다. 이는 발효 검정콩 추출액에서도 강력한 전자공여능이 관찰됨으로써 홍국발효 검정콩이 항비만과 간기능 개선효과에 있어 좋은 소재가 될 수 있음을 나타낸다.
Figure 2 shows the change in the electron donating ability of the black soybean fermentation according to the present invention, the electron donating ability of the hot water extract of black soybean fermentation per mL showed the lowest tendency in B3 used as a control. This suggests that strong electron donating ability in fermented black soybean extract can be a good material for anti-obesity and liver function improvement effect.
[실시예 7] 수퍼옥사이드디스뮤타제(superoxide dismutasee: SOD) 유사활성Example 7 Superoxide Dismutasee (SOD) -like Activity
SOD는 XO에 의하여 또는 약물의 남용, 자외선, 흡연, 피로, 각종 질환 시에 생성되는 활성산소종을 과산화수소로 전환시키는데 관여하는 효소이다. 생체 내에는 효소는 아니나 SOD와 동일한 활성을 가진 물질이 나타내는 활성을 SOD 유사활성이라 한다. 이 활성에 의하여 생성되는 과산화수소 역시 강산 산화작용을 하나 체내에 존재하는 카타라제(catalase)에 의하여 물로 전환됨으로써 독성이 없어진다. 그러므로 SOD 유사활성도 산화적 장애를 방어하는 지표로 활용된다.SOD is an enzyme that is involved in the conversion of free radicals into hydrogen peroxide, produced by XO or in drug abuse, ultraviolet light, smoking, fatigue, and various diseases. The activity exhibited by a substance that is not an enzyme but has the same activity as SOD in vivo is called SOD-like activity. Hydrogen peroxide produced by this activity also undergoes strong acid oxidation, but becomes toxic by conversion to water by catalase present in the body. Therefore, SOD-like activity is also used as an indicator against oxidative disorders.
Martin 등 (1987)의 방법에 따라 0.1mM EDTA 함유 50mM 인산완충액(pH 7.4) 2.94 mL에 시료 일정량을 가해 25℃에서 5분간 가온한 다음 5mM hematoxylin 용액을 가해 10분간 반응시켜 560nm에서 흡광도를 측정하였다. 활성도는 hematoxylin의 자동산화를 50% 억제하는 정도를 1 unit로 계산하였다.According to the method of Martin et al. (1987), a predetermined amount of a sample was added to 2.94 mL of 0.1 mM EDTA-containing 50 mM phosphate buffer (pH 7.4), warmed at 25 ° C. for 5 minutes, and then reacted for 5 minutes with 5 mM hematoxylin solution to measure absorbance at 560 nm. . Activity was calculated as 1 unit to inhibit the automatic oxidation of
도 3에서는 Monascus속 곰팡이를 이용한 검정콩 발효 추출액의 SOD 유사활성을 조사하였다. 그 결과 대조군에서는 SOD 유사 활성이 나타나지 않았고, B2M2와 B3MG에서 가장 높은 활성을 나타내었다. 이와 같은 현상은 검정콩 발효 중에 새로운 SOD 유사활성을 가지는 물질이 생성됨을 나타낸다. In Figure 3 was investigated the SOD-like activity of black soybean fermentation extract using Monascus fungus. As a result, there was no SOD-like activity in the control group, and showed the highest activity in B2M2 and B3MG. This phenomenon indicates that a new SOD-like activity is produced during black bean fermentation.
B2M2에서는 B2M3, B2M4, B3MG에 비하여 총 폴리페놀 함량은 다소 감소하였으나 전자공여능과 SOD유사활성은 거의 대등한 함량을 나타내거나 더 높은 경향을 나타내었다. In B2M2, the total polyphenol content was slightly decreased compared to B2M3, B2M4, and B3MG, but electron donating ability and SOD-like activity were almost equal or higher.
검정콩 발효물 mg/mL당의 SOD(수퍼옥사이드디스뮤타제) 유사 활성은 B3MG가 B2M2 나 B3ME, B3MH, MPM에 비하여 다소 낮았으나, 폴리페롤 mg당의 활성은 B3MG가 MPM에 비하여는 활성이 월등하게 높았다.
The SOD (superoxide dismutase) -like activity per mg / mL of black soybean fermentation was slightly lower than that of B2M2, B3ME, B3MH, or MPM, but the activity per mg of polyferol was significantly higher than that of MPM. .
[실시예 8] 홍국발효 검정콩에서 모나콜린-K의 추출 및 정량Example 8 Extraction and Quantitation of Monacholine-K from Fermented Black Soybean
상기 표 1의의 시료에서 모나콜린-K를 추출하여 그 함량을 측정하여 비교하였다. 모나콜린-K는 콜레스테롤 합성을 저해하는 물질이므로, 이 물질의 함량이 높으면 비만 저해 활성이 높을 것으로 생각된다.
Monacholine-K was extracted from the sample of Table 1 and its content was measured and compared. Since monacholine-K is a substance that inhibits cholesterol synthesis, a high content of this substance is considered to be high in obesity inhibitory activity.
8-1: 모나콜린-K를 추출하기 위한 시험방법 및 분석기기조건8-1: Test Method and Analyzer Conditions for Extracting Monacholine-K
함량 시험에 대한 시료 전처리 조건 및 분석기기 조건은 하기 표 2에 기재된 설정한 기준 및 시험방법에 기술한 조건으로 시험하였다.
Sample pretreatment conditions and analyzer conditions for the content test were tested under the conditions described in the criteria and test methods set forth in Table 2 below.
[표 2]TABLE 2
8-2: 홍국발효 검정콩 추출물 중 MK와 MKA 함량 시험8-2: MK and MKA Content Test in Fermented Black Soybean Extract
직선성 시험용액의 조제 (MK):Preparation of Linearity Test Solution (MK):
시험용액 조제는 모나콜린 K(Monacolin K lactone form, ChromaDex Inc. USA) 5 mg을 정확히 취하여 MeOH로 정확히 50 ㎖로 정용, 시험용액으로 하였다. 표준 용액(각 100 ㎍/ml)을 MeOH로 희석하여 6 농도의 시험용액을 조제하였다. 시험 용액에서의 농도는 24.54, 9.82, 4.91, 2.45, 1.23, 0.49 ㎍/ml이 되도록 하였다. 시험 용액을 각각 0.45 ㎛ 멤브레인 필터로 여과한 후 20 ㎕를 취하여 HPLC에 주입하여 분석하였다.
The test solution was prepared by accurately taking 5 mg of Monacolin K lactone form (ChromaDex Inc. USA) and using 50 mg of MeOH as the standard solution. A standard solution (100 μg / ml each) was diluted with MeOH to prepare 6 concentrations of test solution. The concentrations in the test solution were 24.54, 9.82, 4.91, 2.45, 1.23, 0.49 μg / ml. The test solutions were each filtered through a 0.45 μm membrane filter and 20 μl were taken and analyzed by injection into HPLC.
MK 표준품의 akaline hydrolysis에 의한 MKA의 제조: Preparation of MKA by akaline hydrolysis of MK Standards:
직선성 시험용액의 조제 (MKA):Preparation of Linearity Test Solution (MKA):
시험용액 조제는 반응시켜서 얻은 용액(MK)을 100 ㎍/ml로 하고 시험용액으로 하였다. 시험용액 (각 100㎍/ml)을 50% EtOH로 희석하여 7 농도의 시험용액을 조제하였다. 시험용액에서의 농도는 24.27, 9.71, 4.85, 2.43, 1.21, 0.49 ㎍/ml이 되도록 하였다. 시험용액을 각각 0.45 ㎛ 멤브레인 필터로 여과한 후 20 ㎕를 취하여 HPLC에 주입하여 분석하였다.The test solution preparation was made into 100 g / ml of the solution (MK) obtained by reaction, and it was set as the test solution. A test solution (100 μg / ml each) was diluted with 50% EtOH to prepare a test solution at 7 concentrations. The concentration in the test solution was 24.27, 9.71, 4.85, 2.43, 1.21, 0.49 μg / ml. Each test solution was filtered through a 0.45 μm membrane filter and 20 μl was taken and analyzed by injection into HPLC.
도 4는 모나콜린-K를 추출하여 함량을 측정한 결과를 나타낸 것이다. 도 4에 나타난 것과 같이, 대조군인 B3에서는 모나콜린-K가 검출되지 않았다. 도 4에서 M-2로 표시된 것은, 비지에 Monascus pilosus KCCM 60084 종균 10 중량% 을 접종하여 28℃에서 30일간 배양한 것이다. 이 방법을 이용한 것보다 본 발명에 따른 홍국균을 이용한 검정콩 발효물에서 모나콜린-K가 많이 검출됨을 알 수 있다.
Figure 4 shows the result of measuring the content by extracting Monacholine-K. As shown in Figure 4, Monacholine-K was not detected in the control group B3. In FIG. 4, indicated by M-2 is inoculated with 10% by weight of 10% by weight of seeded Monascus pilosus KCCM 60084 incubated at 28 ° C. for 30 days. Rather than using this method, it can be seen that monacoline-K is more detected in fermented black soybeans using the present invention.
[실시예 9] 실험동물에서의 비만 효과 Example 9 Obesity Effect in Experimental Animals
9-1: 실험 동물 및 기본 식이9-1: Experimental Animals and the Basic Diet
상기 실시예 3에서 조제한 검정콩 홍국 발효물의 항비만 효과에 미치는 영향을 조사하기 위하여, 실험동물은 2011년 5월 9~10일에 출생하여 4주령이 된 평균체중 21~24g, CrljOrli;CD1 (ICR) 계통의 SPF/VAF outbred mice를 (주)오리엔트바이오(성남시, 경기도, 한국)으로부터 구입하여 일주일간 기본식이 만을 공급하여 환경에 적응하게 하였다. 기본식이는 5L79 Rat/Mouse Formula 18%(PMI Nutrition LLC, Po Box 19798 Brentwood Mo63144, USA)로 crude porotein(minimum) 18%, crude fat(minimum 5%, fiber(maximum) 5%, ash(maximum) 8%, carbohydrate 64%인 것을 사용하였다. In order to investigate the effect on the anti-obesity effect of black soybean red yeast ferment prepared in Example 3, the experimental animals were born on May 9-10, 2011, the average weight of 21-24 g, CrljOrli; CD1 (ICR ) SPF / VAF outbred mice were purchased from Orient Bio Co., Ltd. (Seongnam-si, Gyeonggi-do, Korea). The basic diet is 5L79 Rat / Mouse Formula 18% (PMI Nutrition LLC, Po Box 19798 Brentwood Mo63144, USA), crude porotein (minimum) 18%, crude fat (minimum 5%, fiber (maximum) 5%, ash (maximum) 8% and carbohydrate 64% were used.
9-2: 실험 구분9-2: Experiment
7일간 환경에 적응시킨 실험 동물은 무작위로 6마리씩으로 구분하여 정상군(기본사료 급여군: NC), 고지방식이 대조군(기본사료에 라아드 37.54% 함유, 기본사료에 함유된 지방 포함 : HC), HC+Biji급여군(라이드 37.54% 및 비지 2%함유: Biji), HC+MA급여군(라이드 37.54% 및 비지에 Monascus pilosus KCCM 60084 종균 10 중량% 을 접종하여 28℃에서 30일간 배양한 발효물 2%함유: MA), HC+B3MG급여군(라이드 37.54% 및 B3MG 발효물 2%함유: B3MG)의 5개군으로 구분하였다. 하기 표 3은 Biji, MA, B3MG의 성분을 파이버(Fiber)로 계산하여 환산하여 나타낸 것이다.
Experimental animals adapted to the environment for 7 days were randomly divided into 6 groups, which were normal group (basic feed group: NC), and high-fat diet control group (37.54% of Raad in the basic diet, and fat contained in the basic feed: HC ), HC + Biji feeding group (37.54% Ride and 2% biji: Biji), HC + MA feeding group (37.54% Ride and B. inoculated with 10% by weight of Monascus pilosus KCCM 60084 spawn incubated at 28 ° C for 30 days It was divided into five groups: 2% fermented products: MA), HC + B3MG-treated group (37.54% of the Ride and 2% B3MG fermented products: B3MG). Table 3 shows the components of Biji, MA, and B3MG in terms of fiber.
[표 3] [Table 3]
9-3: 사육 방법9-3: Breeding Method
실험식이는 매일 오전 10시에 50g씩 공급한 후 남은 양을 제외한 것을 식이량으로 하였으며, 물은 매일 수돗물을 공급하였다. 실험군의 식이는 10일간 공급할 양을 제조하여 4℃에 냉장보관하면서 매일 신선한 식이를 공급하였다. 사육장은 스테인레스 장을 사용하였고, 온도 및 습도는 22±2℃, 60±5%로 조정하였고, 명암은 6:00 Am~6:00 Pm으로 명암 사이클을 유지하였다.
Experimental diet was 50g at 10 am every day except for the remaining amount was the dietary amount, water was supplied daily tap water. The diet of the experimental group was prepared for the amount to be supplied for 10 days, and kept fresh at 4 ° C. while refrigerated. The kennel was made of stainless steel, and the temperature and humidity were adjusted to 22 ± 2 ° C and 60 ± 5%, and the contrast was maintained from 6:00 Am to 6:00 Pm.
9-4: 체중증가량, 식이섭취량, 음용수섭취량 및 식이 효율 9-4: Weight gain, dietary intake, drinking water intake and dietary efficiency
체중, 식이 및 음용수 섭취량은 전 실험기간을 통하여 매일 일정한 시간에 측정하였다. 식이효율(food efficiency ratio, FER)은 같은 기간 동안의 체중증가량을 동일기간의 식이섭취량으로 나눈 값으로 하였다. Body weight, diet and drinking water intake were measured at regular times every day throughout the entire experimental period. The food efficiency ratio (FER) was calculated by dividing the weight gain during the same period by the food intake during the same period.
9-5: 통계 처리9-5: Statistics processing
모든 실험결과는 실험동물 6마리의 평균치와 표준편차로 나타내었으며, 유의성 검증은 SPSS (Statistical Package for Social Sciences, Version 12, SPSS Inc., Chicago, IL, USA) software package program을 이용하여 Duncan's multiple range test를 행하였다.
All experimental results were expressed as mean and standard deviation of 6 experimental animals, and significance test was performed using Duncan's multiple range using the Statistical Package for Social Sciences, Version 12, SPSS Inc., Chicago, IL, USA test was performed.
9-6: 체중증가량, 식이섭취량, 식이효율 및 배변량9-6: weight gain, dietary intake, dietary efficiency and defecation
비만을 유도한 실험동물을 표 2의 식이조성과 실험구분에 따라 7주간 사육하는 동안의 체중변화는 도 5와 같다. 체중증가량, 식이섭취량, 식이효율을 조사한 결과는 하기 표 4와 같다. 7주간 사육하는 동안 정상대조군(NC)에서는 지속적인 체중증가를 보인 반면 비만유도 후 고지방과 고콜레스테롤 식이를 급여한 비만대조군(HC)는 4주 까지는 급속한 증가를 보였으나 그 이후는 체중의 증가가 완만하였고 비지 급여군(Biji)은 급여초기부터 체중이 증가하기 시작하여 약 4주째에는 상당한 체중증가를 나타내었으나 그 이후부터 HC군과의 차이가 좁혀지기 시작하여 7주째는 HF군과 유사한 체중을 나타내었다. 그러나 홍국발효 검정콩군(B3MG)은 2주째까지는 HF군과 유사한 체중증가를 보였으나 그 이후부터 차이를 보이기 시작하여 7주째는 NC군과 비슷한 체중을 나타내어 현저한 체중감소 효과를 나타내었다. 7주째의 체중과 초기 체중의 차이로부터 산출한 1주당 평균 체중증가량은 HC군이 4.66 g인데 비하여 비지(Biji)와 홍국발효 급여군(B3MG)은 각각 3.77 g 및 3.75 g으로 HC군에 비하여 각각 19.1% 및 19.5%의 감소를 나타내었으며 B3MG의 경우는 3.25 g 으로 30.3% 감소를 나타내었다. B3MG의 경우는 1일 평균 식이섭취량은 NC군 31.63 g이었으나 HC, Biji 및 MA군은 27.38~34.98g으로 유의적인 차이가 없었다. Obesity-induced body weight change during the seven weeks of breeding the experimental animals according to the dietary composition and experimental classification of Table 2 is shown in FIG. The results of the weight gain, dietary intake, and dietary efficiency are shown in Table 4 below. During the seven-week breeding period, the normal control group (NC) continued to gain weight, while the obese control group (HC) fed a high-fat and high-cholesterol diet after obesity induction showed a rapid increase until four weeks, but since then, weight gain has been slow. Biji group gained weight from the beginning of salary and showed significant weight gain at about 4 weeks, but since then, the difference with HC group began to narrow and showed similar weight to HF group at 7 weeks. It was. However, the red yeast fermented black soybean group (B3MG) showed similar weight gains to the HF group until 2 weeks, but began to show a difference afterwards, and showed similar weight to the NC group at 7 weeks. The average weight gain per week calculated from the difference between the seventh week weight and the initial weight was 4.66 g in HC group, and 3.77 g and 3.75 g in fermented BJG and BJG, respectively, compared to HC group. Reductions of 19.1% and 19.5% were observed, and for B3MG, 3.25 g showed a 30.3% reduction. In the case of B3MG, the average daily dietary intake was 31.63 g in the NC group, but there was no significant difference in the HC, Biji and MA groups from 27.38 to 34.98 g.
본 발명에서 B3MG군이 HC군과 Biji 및 MA군에 비하여 식이섭취량에서나 배변량에서 뚜렷한 차이를 보이지 않음에도 B3MG에 비하여 높은 체중감소율을 보였다.
In the present invention, the B3MG group showed a higher weight loss rate than the B3MG group, although the HC3 and Biji and MA groups did not show any significant difference in dietary intake or defecation.
[표 4] TABLE 4
9-7: 간 중량 및 복부지방 함량 9-7: Liver weight and abdominal fat content
콜레스테롤 함유 고지방 식이로 비만을 유도한 다음 7주간 실험식이를 급여한 흰쥐의 체중 당 간 중량(%)과 복부지방 함량을 측정한 결과는 표 5와 같다. 체중당 간 중량(%)은 모든 실험군에서 NC군에 비해 유의하게 증가하였으며, B3MG은 HC군에 비하여 유의한 감소를 보였다.
Table 5 shows the results of measuring the liver weight (%) and the abdominal fat content of the rats fed the experimental diet for 7 weeks after inducing obesity with a cholesterol-containing high fat diet. Liver weight (%) per body weight was significantly increased in all experimental groups compared to NC group, and B3MG was significantly decreased in comparison with HC group.
[표 5]TABLE 5
이상의 실험결과에서 특히 B3MG군에서, HC군에 비하여, 식이섭취량의 저하 없이 증체량과 식이효율 뿐만 아니라 체중 당 간 중량(%)이 유의하게 감소하는 것은 홍국균 추출물이 비만을 경감 및 예방시킬 수 있음을 알 수 있다. 즉, 검정콩을 홍국균으로 발효시킴으로써 항비만 효능이 우수한 홍국검정콩 발효물을 제조할 수 있다.
In the above experimental results, especially in the B3MG group, compared to the HC group, the significant reduction in weight gain and dietary efficiency as well as weight per liver weight (%) without lowering the dietary intake, suggesting that the extract of Hong Kong bacteria can reduce and prevent obesity. Able to know. In other words, fermented black soybean fermented with excellent anti-obesity effect by fermenting black soybeans with red yeast.
Claims (8)
상기 증자된 검정콩에 모나스커스 퍼푸레우스(M. purpureus), 모나스커스 필로수스(M. pilosus), 모나스커스 루버(M. ruber) 및 모나스커스 카올리앙(M. kaoliang) 중에서 선택된 하나 이상의 홍국균 종배양액을 접종하고 발효시키는;
단계를 포함하고,
상기 홍국균 종배양액은 감자한천배지(PDA 배지)에서 배양한 홍국균을 액체 영양배지(S-INAE)에 접종하여 배양한 것을 특징으로 하는 항비만 활성을 갖는 검정콩 발효물의 제조방법.
Add black beans; And
The increase in the soybean Pseudomonas coarse fur pure mouse (M. purpureus), Pseudomonas coarse Philo Versus (M. pilosus), Pseudomonas coarse louver (M. ruber) and Pseudomonas coarse car up hem (M. kaoliang) one or more selected from honggukgyun Inoculating and fermenting the seed culture solution;
Including steps
The hongguk species culture medium is a method for producing a black soybean fermentation product having an anti-obesity activity, characterized in that the culture was inoculated in a liquid nutrient medium (S-INAE) cultured in potato agar medium (PDA medium).
The method of claim 4, wherein the black bean is selected from the group consisting of black beans, crushed black beans, germinated black beans, roasted black beans, and processed products thereof.
The fermentation step of the black bean fermentation having anti-obesity activity, characterized in that the fermentation of the hongkuk seed culture medium in a weight ratio of 1-10% by weight to the black soybean for 10 to 40 days at 20 ~ 30 ℃ Method of producing water.
The method of claim 4 wherein the composition of the liquid nutrient medium (S-INAE) is rice flour 2.0 g, glucose 3.0 g, peptone 2.0 g, KH 2 PO 4 0.8 g, MgSO 4? 7H 2 O 0.05 g, sodium nitrate 0.2 g, NaCl 0.1 g, d-water 100 mL preparation ratio and a method for producing a black bean fermented product having anti-obesity activity, characterized in that the medium of the initial pH 6.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110091137A KR101145181B1 (en) | 2011-09-08 | 2011-09-08 | Black soybean fermentation by monascus sp. for production of body weight reducing material |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110091137A KR101145181B1 (en) | 2011-09-08 | 2011-09-08 | Black soybean fermentation by monascus sp. for production of body weight reducing material |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101145181B1 true KR101145181B1 (en) | 2012-05-14 |
Family
ID=46271955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110091137A KR101145181B1 (en) | 2011-09-08 | 2011-09-08 | Black soybean fermentation by monascus sp. for production of body weight reducing material |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101145181B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101232845B1 (en) | 2011-07-20 | 2013-02-13 | 이현구 | Media composition containing soy, fermented soy product, and composition for weight control containing the same |
KR101391632B1 (en) * | 2012-09-06 | 2014-05-07 | 명지대학교 산학협력단 | Dried persimmon with functionality and preparing method thereof |
KR101542909B1 (en) * | 2012-10-18 | 2015-08-07 | 한국생명공학연구원 | Monascus Strain Suitable for liquid fermentation of Ultra Finely Pulverized Substrate and Uses Thereof |
KR101852504B1 (en) * | 2016-09-20 | 2018-04-26 | 성신여자대학교 산학협력단 | Monascus-fermented black bean vinegar, method for manufacturing thereof and application thereof |
WO2022149697A1 (en) * | 2021-01-07 | 2022-07-14 | 주식회사 엠바이옴쎄라퓨틱스 | Anti-obesity composition containing, as active ingredient, moringa oleifera fermentation product prepared using novel monascus purpureus sl1 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006121989A (en) | 2004-10-29 | 2006-05-18 | Gunze Ltd | Soybean monascus and method for producing the same |
JP2006296251A (en) | 2005-04-19 | 2006-11-02 | Gunze Ltd | alpha-GLUCOSIDASE INHIBITOR |
JP2007267637A (en) | 2006-03-30 | 2007-10-18 | Gunze Ltd | Soybean monoscus-containing fermented soybean paste |
JP2011109943A (en) | 2009-11-25 | 2011-06-09 | Gunze Ltd | Soybean monascus and method for producing the same |
-
2011
- 2011-09-08 KR KR1020110091137A patent/KR101145181B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006121989A (en) | 2004-10-29 | 2006-05-18 | Gunze Ltd | Soybean monascus and method for producing the same |
JP2006296251A (en) | 2005-04-19 | 2006-11-02 | Gunze Ltd | alpha-GLUCOSIDASE INHIBITOR |
JP2007267637A (en) | 2006-03-30 | 2007-10-18 | Gunze Ltd | Soybean monoscus-containing fermented soybean paste |
JP2011109943A (en) | 2009-11-25 | 2011-06-09 | Gunze Ltd | Soybean monascus and method for producing the same |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101232845B1 (en) | 2011-07-20 | 2013-02-13 | 이현구 | Media composition containing soy, fermented soy product, and composition for weight control containing the same |
KR101391632B1 (en) * | 2012-09-06 | 2014-05-07 | 명지대학교 산학협력단 | Dried persimmon with functionality and preparing method thereof |
KR101542909B1 (en) * | 2012-10-18 | 2015-08-07 | 한국생명공학연구원 | Monascus Strain Suitable for liquid fermentation of Ultra Finely Pulverized Substrate and Uses Thereof |
KR101852504B1 (en) * | 2016-09-20 | 2018-04-26 | 성신여자대학교 산학협력단 | Monascus-fermented black bean vinegar, method for manufacturing thereof and application thereof |
WO2022149697A1 (en) * | 2021-01-07 | 2022-07-14 | 주식회사 엠바이옴쎄라퓨틱스 | Anti-obesity composition containing, as active ingredient, moringa oleifera fermentation product prepared using novel monascus purpureus sl1 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102389139B (en) | Preparation method for edible fungus nutritional health-care functional drink | |
Eleazu et al. | Effect of partial replacement of wheat flour with high quality cassava flour on the chemical composition, antioxidant activity, sensory quality, and microbial quality of bread | |
KR101145181B1 (en) | Black soybean fermentation by monascus sp. for production of body weight reducing material | |
KR20120125042A (en) | A process for preparing a fermented broth of herbal medicine by combined microorganisms, a fermented broth prepared by the process, and a fermented food prepared by the fermented broth | |
KR101376312B1 (en) | Functional persimmon vinegar and preparing method thereof | |
Kardong et al. | Evaluation of Nutritional and Biochemical aspects of Po: ro apong (Saimod)-A home made alcoholic rice beverage of Mising tribe of Assam, India | |
Chen et al. | Influence of fermentation on antioxidant and hypolipidemic properties of maifanite mineral water-cultured common buckwheat sprouts | |
KR101428692B1 (en) | Fermented Organic Rubus Coreanus Vinegar With Antioxidative Function And Process Of Preparing The Same | |
CN110973423A (en) | Red yeast noni beverage and preparation method thereof | |
JP6597992B2 (en) | Method for producing polyphenol-containing culture and polyphenol-containing culture | |
JP7007644B2 (en) | Manufacturing method of lactic acid bacteria, fermented lactic acid bacteria food, blood pressure regulator, and fermented lactic acid bacteria food | |
KR101738753B1 (en) | Healthful composition using Mapleleaf Aisnsliaea extracts, and funtional drinks comprising the same | |
KR101984400B1 (en) | Process for producing antioxidant and anti-fatigue efficacy of mulberry vinegar | |
KR20140034981A (en) | Method for increasing resveratrol content of peanut sprouts and foods in resveratrol of peanut sprouts | |
CN115251203B (en) | Application of Xie Washi aspergillus in preparing peony petal tea by fermentation and method | |
KR101391632B1 (en) | Dried persimmon with functionality and preparing method thereof | |
KR101381950B1 (en) | Fermented tea of persimmon leaf and manufacturing method of the same | |
KR102070613B1 (en) | Fermented products using dendropanax morbifera and sweet potatoes, their preparation method, and functional products using the same | |
KR101392348B1 (en) | Functional persimmon chip and preparing method thereof | |
CN112314744A (en) | Ganoderma lucidum fermented black tea and preparation method thereof | |
Bishop et al. | Chemical composition of Kombucha. Beverages. 2022; 8: 45 | |
KR20010069775A (en) | a manufacturing process and feeds which be made from a Tofuwast redkoji containing monacolin | |
KR20180055710A (en) | Fermentation product of seomae mugwort with high palatability and functionality, and method for preparing the same | |
KR101915180B1 (en) | Lotus Leached Tea and Manufacturing Method Thereof | |
Goswami | Modulation of bioactive compounds in underutilized legume horse gram (Macrotyloma uniflorum) by germination and fermentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150506 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160503 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170504 Year of fee payment: 6 |
|
R401 | Registration of restoration |